Ferric Citrate and Chronic Kidney Disease in Children
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
We will conduct a 12-month, double-blind, randomized, placebo-controlled trial to assess the
effects of therapy with ferric citrate (FC) on changes in intact FGF23 levels (iFGF23,
primary endpoint) in 160 pediatric patients (80 in each of the two arms) aged 6-17 years of
either sex with chronic kidney disease (CKD) stages 3-4 and age-appropriate normal serum
phosphate levels. Participants will be randomized to one of the two groups: 1) FC or 2) FC
placebo. Participants will be recruited from 12 core clinical sites.
Phase:
Phase 2
Details
Lead Sponsor:
University of California, Los Angeles
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)